337 related articles for article (PubMed ID: 16399902)
1. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC
Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902
[TBL] [Abstract][Full Text] [Related]
2. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions.
Marchetti B; Serra PA; Tirolo C; L'episcopo F; Caniglia S; Gennuso F; Testa N; Miele E; Desole S; Barden N; Morale MC
Brain Res Brain Res Rev; 2005 Apr; 48(2):302-21. PubMed ID: 15850669
[TBL] [Abstract][Full Text] [Related]
4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
5. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
6. Interactions between environmental and genetic factors in the pathophysiology of Parkinson's disease.
Tsang F; Soong TW
IUBMB Life; 2003 Jun; 55(6):323-7. PubMed ID: 12938734
[TBL] [Abstract][Full Text] [Related]
7. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
Tripanichkul W; Sripanichkulchai K; Finkelstein DI
Brain Res; 2006 Apr; 1084(1):28-37. PubMed ID: 16564034
[TBL] [Abstract][Full Text] [Related]
8. Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
Morale MC; L'Episcopo F; Tirolo C; Giaquinta G; Caniglia S; Testa N; Arcieri P; Serra PA; Lupo G; Alberghina M; Harada N; Honda S; Panzica GC; Marchetti B
Brain Res Rev; 2008 Mar; 57(2):431-43. PubMed ID: 18063054
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.
McLaughlin P; Zhou Y; Ma T; Liu J; Zhang W; Hong JS; Kovacs M; Zhang J
Glia; 2006 Apr; 53(6):567-82. PubMed ID: 16419087
[TBL] [Abstract][Full Text] [Related]
10. The MPTP model of Parkinson's disease.
Smeyne RJ; Jackson-Lewis V
Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
[TBL] [Abstract][Full Text] [Related]
11. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.
Dietz GP; Stockhausen KV; Dietz B; Falkenburger BH; Valbuena P; Opazo F; Lingor P; Meuer K; Weishaupt JH; Schulz JB; Bähr M
J Neurochem; 2008 Feb; 104(3):757-65. PubMed ID: 17995935
[TBL] [Abstract][Full Text] [Related]
12. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens.
Gillies GE; McArthur S
Horm Behav; 2010 Jan; 57(1):23-34. PubMed ID: 19538962
[TBL] [Abstract][Full Text] [Related]
13. Inflammation in Parkinson's disease: causative or epiphenomenal?
Hald A; Van Beek J; Lotharius J
Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide.
Morale MC; Serra PA; Delogu MR; Migheli R; Rocchitta G; Tirolo C; Caniglia S; Testa N; L'Episcopo F; Gennuso F; Scoto GM; Barden N; Miele E; Desole MS; Marchetti B
FASEB J; 2004 Jan; 18(1):164-6. PubMed ID: 14630699
[TBL] [Abstract][Full Text] [Related]
15. Iron transport in Parkinson's disease.
Hirsch EC
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
[TBL] [Abstract][Full Text] [Related]
16. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald A; Lotharius J
Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
[TBL] [Abstract][Full Text] [Related]
18. Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia.
Mena MA; García de Yébenes J
Neuroscientist; 2008 Dec; 14(6):544-60. PubMed ID: 19029058
[TBL] [Abstract][Full Text] [Related]
19. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
Sriram K; Miller DB; O'Callaghan JP
J Neurochem; 2006 Feb; 96(3):706-18. PubMed ID: 16405514
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
